Afghanistan has a potential market for pharmaceutical products. Based on NHA’s research, pharmaceutical spending accounts for 26% of total annual health spending, amounting to over $450 million USD. Clinical studies between 2004 – 2013 show that about 90% of people are not pleased with the imported medicine, but due to the lack of domestic production they are left with no another option. In the absence of domestic pharmaceutical products, Snow Pharma is fully committed to manufacturing pharmaceutical products which will be sold in the market by its high quality, low price, and nation-wide accessibility. Furthermore, the stakeholders of Snow Pharma Ltd, who have years of experience in pharmaceutical, are willing to promote Snow Pharma’s marketing to the best of their ability. Snow Pharma’s quality and vision will soon lead to immensely quick growth in the market.